A name that they have looked at over time. It is a stock that has not done much for a long time. China is a big market, and it should benefit from 5g rollout but it has not been reflected in the stock price. There are safer investments elsewhere, such as Verizon.

It has been a winner so far, despite some pullback recently. It is part of the thematic play that has been accelerated by covid. There are a lot of instances where it is more practical for the practitioner and the client to consult through telemedicine. Adoption will continue to rise over time.

Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.

The valuation is still high and it is not cheap. It is a long-term winner. The numbers from the report were still good. Despite a decline in iPhone sales, he believes we will see a pickup in sales next year. The iPhone is no longer the sole driver, with other parts of the business growing at 25% yoy. They are innovating in the wearables and service side of the business.

Likes gold. The environment is favourable for gold, where interest rates are staying low for at least a couple years. We have come off recent highs but we are up on the year. So long as real interest rates stay low, it is good. Barrick or Franco-Nevada, the big-cap names, would be his choice.

The issues is that the market has been challenging for them. Their recent results were horrendous. Data centres are not doing well, and this was their bright spot. AMD reported great numbers, so it is the company that is not preforming. AMD is also ahead of Intel for technology and they will probably erode marketshare from Intel.

The tobacco space looks cheap but there is a secular overhang. They are highly profitable but eventually, tobacco sales will disappear. ESG is also a force. Institutional investors may not be able to own this.